Routine lung volume recruitment in boys with Duchenne muscular dystrophy: a randomised clinical trial.
Duchenne muscular dystrophy
child
lung volume recruitment
randomized controlled trial
respiratory therapy
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
08
09
2021
accepted:
25
01
2022
pubmed:
4
3
2022
medline:
28
7
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
Impaired cough results in airway secretion retention, atelectasis and pneumonia in individuals with Duchenne muscular dystrophy (DMD). Lung volume recruitment (LVR) stacks breaths to inflate the lungs to greater volumes than spontaneous effort. LVR is recommended in DMD clinical care guidelines but is not well studied. We aimed to determine whether twice-daily LVR, compared with standard of care alone, attenuates the decline in FVC at 2 years in boys with DMD. In this multicentre, assessor-blinded, randomised controlled trial, boys with DMD, aged 6-16 years with FVC >30% predicted, were randomised to receive conventional treatment or conventional treatment plus manual LVR twice daily for 2 years. The primary outcome was FVC % predicted at 2 years, adjusted for baseline FVC % predicted, age and ambulatory status. Secondary outcomes included change in chest wall distensibility (maximal insufflation capacity minus FVC) and peak cough flow. Sixty-six boys (36 in LVR group, 30 in control) were evaluated (median age (IQR): 11.5 years (9.5-13.5), median baseline FVC (IQR): 85% predicted (73-96)). Adjusted mean difference in FVC between groups at 2 years was 1.9% predicted (95% CI -6.9% to 10.7%; p=0.68) in the direction of treatment benefit. We found no differences in secondary outcomes. There was no difference in decline in FVC % predicted with use of twice-daily LVR for boys with DMD and relatively normal lung function. The burden associated with routine LVR may outweigh the benefit. Benefits of LVR to maintain lung health in boys with worse baseline lung function still need to be clarified. NCT01999075.
Sections du résumé
BACKGROUND
Impaired cough results in airway secretion retention, atelectasis and pneumonia in individuals with Duchenne muscular dystrophy (DMD). Lung volume recruitment (LVR) stacks breaths to inflate the lungs to greater volumes than spontaneous effort. LVR is recommended in DMD clinical care guidelines but is not well studied. We aimed to determine whether twice-daily LVR, compared with standard of care alone, attenuates the decline in FVC at 2 years in boys with DMD.
METHODS
In this multicentre, assessor-blinded, randomised controlled trial, boys with DMD, aged 6-16 years with FVC >30% predicted, were randomised to receive conventional treatment or conventional treatment plus manual LVR twice daily for 2 years. The primary outcome was FVC % predicted at 2 years, adjusted for baseline FVC % predicted, age and ambulatory status. Secondary outcomes included change in chest wall distensibility (maximal insufflation capacity minus FVC) and peak cough flow.
RESULTS
Sixty-six boys (36 in LVR group, 30 in control) were evaluated (median age (IQR): 11.5 years (9.5-13.5), median baseline FVC (IQR): 85% predicted (73-96)). Adjusted mean difference in FVC between groups at 2 years was 1.9% predicted (95% CI -6.9% to 10.7%; p=0.68) in the direction of treatment benefit. We found no differences in secondary outcomes.
CONCLUSION
There was no difference in decline in FVC % predicted with use of twice-daily LVR for boys with DMD and relatively normal lung function. The burden associated with routine LVR may outweigh the benefit. Benefits of LVR to maintain lung health in boys with worse baseline lung function still need to be clarified.
TRIAL REGISTRATION NUMBER
NCT01999075.
Identifiants
pubmed: 35236763
pii: thoraxjnl-2021-218196
doi: 10.1136/thoraxjnl-2021-218196
pmc: PMC9340020
doi:
Banques de données
ClinicalTrials.gov
['NCT01999075']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
805-811Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Pediatrics. 2009 May;123 Suppl 4:S231-5
pubmed: 19420150
Pediatr Pulmonol. 2015 May;50(5):487-94
pubmed: 25755201
ERJ Open Res. 2017 Mar 14;3(1):
pubmed: 28326313
Neuromuscul Disord. 2006 Apr;16(4):249-55
pubmed: 16545568
Spinal Cord. 2006 Apr;44(4):242-8
pubmed: 16151446
Pediatrics. 2009 May;123 Suppl 4:S226-30
pubmed: 19420149
J Rehabil Med. 2017 Jan 19;49(1):49-53
pubmed: 27630091
Ann Am Thorac Soc. 2016 Feb;13(2):217-22
pubmed: 26599476
Respirology. 2019 Jun;24(6):512-520
pubmed: 30408263
Respir Med. 2018 Mar;136:98-110
pubmed: 29501255
Pediatr Pulmonol. 2013 Jan;48(1):59-66
pubmed: 22451223
Am J Phys Med Rehabil. 2008 Sep;87(9):720-5
pubmed: 18716483
Pediatr Pulmonol. 2010 Aug;45(8):739-48
pubmed: 20597083
Lancet Neurol. 2018 Mar;17(3):251-267
pubmed: 29395989
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
Am J Respir Crit Care Med. 2008 Feb 1;177(3):253-60
pubmed: 18006882
Muscle Nerve. 1981 Mar-Apr;4(2):155-64
pubmed: 7207506
Am J Respir Crit Care Med. 2001 Dec 15;164(12):2191-4
pubmed: 11751186
Can Respir J. 2011 Jul-Aug;18(4):197-215
pubmed: 22059178
Sleep Med. 2020 May;69:19-33
pubmed: 32045851
Chest. 2008 Jan;133(1):161-8
pubmed: 18071020
Lancet Neurol. 2018 Apr;17(4):347-361
pubmed: 29395990
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):448-55
pubmed: 26140500
Yonsei Med J. 2006 Apr 30;47(2):184-90
pubmed: 16642546
Thorax. 2012 Jul;67(7):654-5
pubmed: 22718494
Spine (Phila Pa 1976). 2007 Feb 15;32(4):459-65
pubmed: 17304138
Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36
pubmed: 7663792
Pediatrics. 2009 May;123 Suppl 4:S215-8
pubmed: 19420146
Arch Phys Med Rehabil. 2012 Jul;93(7):1117-22
pubmed: 22421625
BMC Med Res Methodol. 2018 May 29;18(1):48
pubmed: 29843614
Lancet Neurol. 2010 Feb;9(2):177-89
pubmed: 19945914
Am J Respir Crit Care Med. 2007 Jun 15;175(12):1266-71
pubmed: 17413124
Chest. 2000 Jul;118(1):61-5
pubmed: 10893360
Am J Phys Med Rehabil. 2000 May-Jun;79(3):222-7
pubmed: 10821306
Am J Phys Med Rehabil. 2002 Jul;81(7):506-11
pubmed: 12131177
Clin Pharmacol Ther. 1974 May;15(5):443-53
pubmed: 4597226